GB2196348A - Synthetic medium for hybridoma and myeloma cell cultivation - Google Patents
Synthetic medium for hybridoma and myeloma cell cultivation Download PDFInfo
- Publication number
- GB2196348A GB2196348A GB08722473A GB8722473A GB2196348A GB 2196348 A GB2196348 A GB 2196348A GB 08722473 A GB08722473 A GB 08722473A GB 8722473 A GB8722473 A GB 8722473A GB 2196348 A GB2196348 A GB 2196348A
- Authority
- GB
- United Kingdom
- Prior art keywords
- cells
- hybridoma
- concentration
- medium
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004408 hybridoma Anatomy 0.000 title claims description 29
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims description 12
- 201000000050 myeloid neoplasm Diseases 0.000 title claims description 12
- 238000004113 cell culture Methods 0.000 title claims description 5
- 210000004027 cell Anatomy 0.000 claims description 52
- 239000001963 growth medium Substances 0.000 claims description 25
- 239000002609 medium Substances 0.000 claims description 24
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 229960002413 ferric citrate Drugs 0.000 claims description 7
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 7
- 239000013589 supplement Substances 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000005569 Iron sulphate Substances 0.000 claims description 4
- 150000002506 iron compounds Chemical class 0.000 claims description 4
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000003139 buffering effect Effects 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- -1 potassium ferricyanide Chemical compound 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000000035 biogenic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000531897 Loma Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001508691 Martes zibellina Species 0.000 description 1
- 102000005717 Myeloma Proteins Human genes 0.000 description 1
- 108010045503 Myeloma Proteins Proteins 0.000 description 1
- 229910003424 Na2SeO3 Inorganic materials 0.000 description 1
- 241000080590 Niso Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 1
- KRGPXXHMOXVMMM-UHFFFAOYSA-N nicotianamine Natural products OC(=O)C(N)CCNC(C(O)=O)CCN1CCC1C(O)=O KRGPXXHMOXVMMM-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000003407 synthetizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/22—Zinc; Zn chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
GB2196348A 1 SPECIFICATION dium are increasing. A number of recipes for
so-called serum-free culture media have been Synthetic medium for hybridoma and mye- proposed where the blood serum is replaced loma cell cultivation by several defined proteins, mostly by trans 70 ferrin, serum albumin and insulin, possibly by The invention relates to a synthetic medium other materials such as unsaturated fatty for hybridoma and myeloma cell cultivation. acids, amines and low molecular hormones Hybridomas obtained by somatic hybridiza- (see J.Kov6f, F. Frank: Methods in Enzymotion of a myeloma cell and of a lymphocyte logy 121: 277,1986).
synthetizing an antibody are industrially used 75 All proteins actually added into culture me- for manufacture of monoclonal antibodies. My- dia for cultivation of hybridoma and myeloma eloma cells, into which by methods of genetic cells have to be free of toxic admixtures, engineering a gene of a biologically active pro- which increases the economic claims on man tein is introduced, for instance a gene of an ufacture. Another drawback of existing cultiva enzyme, an enzyme inhibitor, a hormone, an 80 tion media is the difficult isolation of products immunoregulator, in order to manufacture said of the life activity of hybridoma and myeloma proteins, are equally industrially employed. The cells from culture media, which separation is increasing need of different monoclonal antiaccomplished by repeated separation of re bodies, particularly for therapeutic purposes quired products of protein character from pro and for immunoaffinity chromatography, where 85 teins contained in the culture medium in a kilogram quantities are required, equally as the large excess.
need of different regulating proteins for thera- The mentioned drawbacks are eliminated by peutic purposes, lead to an endeavour to look application of a culture medium according to for more effective and economically more ad- this invention which comprises in addition to vantageous manufacturing methods of said 90 basic components as are anorganic salts in a materials. concentration of 5000 to 12000 mg/l, monoHybridoma and myeloma cells are actually saccharides in a concentration of 300 to 5000 cultivated by first multiplying in laboratory ves- mg/1, amino acids in a concentration of 200 sels such as plastic dishes and bottles, the to 5000 mg/1, vitamines in a concentration of final cultivation and production of the protein 95 2 to 100 mg/1, substances buffering changes is accomplished in an industrial fermentor. The of pH in a concentration of 200 to 20000 monoclonal antibody or some other protein mg/l, possibly sodium pyruvate, antibiotics, an secreted into the cultivation medium is ob- indicator of changes of pH, also a supplement tained from the culture medium after centrifu- formed by at least one water soluble iron gation or filtration of the cells. The isolation of 100 compound in a concentration 2X 10-5 to the produced protein is the more difficult, the 1 X 10-2 mol/I of culture medium, advantage more protein the original culture medium has ously ferric citrate, iron sulphate, ferric chlo contained. The concentration of the produced ride or potassium ferricyanide.
protein, for instance of the monoclonal anti- It is advantageous in case the culture me- body in the cultivation medium is relatively 105 dium contains in combination with the supple low. ment compounds of biogenic trace elements, The synthetic culture medium contains basic particularly of selenium and zinc, ascorbic acid, culture components and a supplement. Basic steroid substances particularly cortisone and culture components are anorganic salts, for in- amines, advantageously ethanolamine, the stance sodium chloride and sodium phosphate, 110 presence of which increases the effectiveness monosaccha rides, for instance glucose or ga- of the supplement.
lactose, amino acids, for instance tryptophan, It has been found, that an entirely indispen- methionine, threonine and glutamine, vita- sable protein component of the serum-free mines, for instance thiamine and nicotinamine, culture medium is transferrin (see J.Kov6f, F.
substances buffering changes of pH, for in- 115 Fran6k: Methods in Enzymology, 121:
stance H-2-hydroxyethylpiperazine-N'-2-ethane 277,1986). As transferrin acts as a transport sulphonic acid, possibly sodium pyruvate, antisubstance of iron from the surrounding me biotics and an indicator of changes of pH. dium into the cell, its functionning could be These basic cultivation components are insuffi- substituted by the presence of water soluble cients for hybridoma and myeloma cells, the 120 iron compounds of a higher concentration than same as for the animal cells and are therefore have been up to now applied in cultivation supplemented by 10% by volume of a blood media. A number of authors (for instance P.D.
serum, for instance cattle-, horse- or fetal bo- Phillips, V.J. Cristofalo in Exp. Cell Res., vine serum. The blood serum introduces into 134:297, 1981 V. Perez. Infante, J.P. Mather the cultivation medium unknown substances, 125 in Exp. Cell Res., 142: 325, 1982; R. Taelle, some of which are supporting the growth of K. Rhyner, J. Castagnola, D.To, J. Mendel cells, others can inhibit the growth. It is there- sohn, J.Clin, Invest., 75:1051,1985) have fore necessary to test the blood serum prior used instead of transferrin water soluble iron to its application and select suitable lots. Thus compounds in concentration of 1 x 10-6 to the costs for manufacture of the culture me- 130 20x 10-6 mol/l. These concentrations are 2 GB2196348A 2 however insufficient in case of hybridoma and of 1,36 x 106 cells/mi within 4 days. The myeloma cells. It has been found that iron number of cells has at this test after 4 days compounds up to a concentration of 1 X 10-2 of cultivation increased fitytimes.
mol/1 are not toxic for hybridoma and mye- Cells of myeloma FO and of hybridomas lorna cells and on the other side concentra- 70 P1-V-01, CMH-02 and T3-03 have been sepa tions of iron compounds higher than 2 X 10-5 rately inocculated to volumes of 1 mi of a mol/1 enable growth of hybridoma and mye- protein-free culture medium of the mentioned lorna cells in a protein-free culture medium. composition contained in wells of a plastic Iron compounds capable to replace transferrin multi-dish with 24 wells. After the first day of are for instance ferric citrate, iron sulphate, 75 cultivation at mentioned conditions the number ferric chloride and potassium ferricyanide. Ef- of cells in a well has been determined and fective concentrations are within limits of after next 24 hours this number has been 2 x 10-5 up to 1 X 10-2 rnol/1. checked again. Thus the mean doubling- time Advantages of the cultivation medium ac- in the exponential growth phase for each hy- cording to this invention is the easy isolation 80 bridoma or myeloma has been determined.
of the protein separated by cells, for instance The mean doubling-time for the myeloma FO of monoclonal antibodies, as the protein se- has been found to be 15,6 h, for the hybri creted by cells is the sole protein which is doma PLV-01 14,8 h, for the hybridoma CMW after cultivation present in the culture medium. 02 14,6 h and for the hybridoma T3-03 11,8 The advantages of the culture medium ac- 85 h.
cording to this invention will be more clearly Cells of the hybridoma PLV01 and of the shown on hand of following examples. hybridoma PGG-05 have been inocculated se parately in a number of 60 x 103 cells to vol Example 1 umes of 1 mi of a protein-free culture medium A basic culture medium which in addition to 90 of the mentioned composition situated in wells the medium RPM1 1640 contained L-glutamine of a plastic multi-dish with 24 wells. For com 1300 ug/mi, sodium pyruvate/ 110 ug/mi/, N- parison cells of the same hybridomas flave 2-hydroxyethylpiperazine-N-2-ethanesulphonic been inocculated into a serum-free culture me acid/ 1,5 x 10-2 Mol/1, penicillin/ 100 units/mi/, dium containing 5 mg/1 of trasnferrin and 10 streptomycin/ 100 ug/mi/ and gentamycin/40 95 mg/l of insulin / SFH medium without lineloic ug/mi/ has been used in order to prepare a acid and albumin, see: J.KovdY and F. Fran6k:
chemically defined protein-free cultivation me- Methods in Enzymology, 121: 277, 1986/.
d[um. The protein-free cultivation medium con- After 4 days of cultivation at above men tained thereafter as substituted of a serum the tioned conditions the number of cells and the following additional materials: ethanolamine 100 concentration of monoclonal antibodies in the /2 x 10-5 mol/1/, ascorbic acid /2 x 10-5 culture medium have been determined using mol/1/, hydrocortisone /5 x 10-9 moi/l/, cad- an enzymoimmunologic test based on the de mium sulphate /CdS0,8/3 H20, 5 x 108 termination of the peroxidase activity. In case mol/1, cobalt chloride, /CoC1,6 H20, 1 X 10 of a growth of the hybridoma PLV-01 in the mol/1, copper sulphate (CUS04.5 H20, 1 X 10-l 105 protein-free medium from an inocculum of moill, ammonium molybdate /NH, Mo,0,,4 60x 103 cells, the concentration of the mono H20, 5.10-10 mol/1, manganese dichloride clonal antibody expressed in relative units of /MnC12.4 H20, 5 x 10- 10 moll], nickel sulphate absorbance had the value of A,,,,=0,298. In /NiSO,.6 H,O, 2,5 x 10-10 mol/1, sodium selen- the comparative experiment carried out in an ite/ /Na2SeO3, 4 x 10-11 moll], sodium silicate 110 SFH medium values of 706 x 103 cells and (Na2SiO,, 2 X 10-7 rnol/1, stannous chloride A4110=0,310 have been obtained. In case of a 1 /SnC1,2 H20, 2,5 x 10-10 mol/1, ammonium growth of the hybridoma PGG-05 in a protein vanadate / W4V03, 2,5 x 10-0 moill, zinc sul- free culture medium for 675x 103 cells, the phate /ZnS0,7 H20, 1 X 10-6 moill and ferric concentration of the monoclonal antibody ex citrate, 5 x 10-4 Mol/1. 115 pressed in relative units of absorbance had Into 6 mi of the protein-free culture medium the value of A = 1,32. In the comparative of the mentioned composition in a Petri dish experiment carried out in an SFH medium (diameter 6 cm) cells of the hybridoma PLVvalues of 731 x 103 cells and A,,,,= 1,26 have 01 have been inocculated in such an amount been obtained.
that the density of cells has been 50x 10.1 120 cells/m]. After 4 days of cultivation in a ther- Example 2 mostat in a humidifed atmosphere of 5% by Cells of a hybridoma PLV-01 have been in- volume of carbon dioxide in air at a tempera- occulated in a number of JOX 103 cells into ture of 37'C, the cells have multiplied to a 0,1 mi of a protein-free cultivation medium of density of 1,53 x 106 cells/m]. The number of 125 the composition as in example 1 placed in cells has thus in the course of cultivation for wells of a plastic cultivation microplate with 4 days multiplied approximately thirtytimes. 96 wells. For comparison purposes cells of By a similar test with cells of the hybridoma this hybridoma have been inocculated into a CMH-02 the cells from an inoculum of protein-free culture medium where ferric chlo 25 x 103 cellsymi have multiplied to a density 130 ride in a concentration of 5 x 10-4 mol/1 re- 3 GB2196348A 3 placed -the ferric citrate. After 3 days of culti- pound is iron sulphate, ferric citrate, ferric vation at conditions as in example 1 the hybri- chloride, potassium ferricyanide.
doma cells have multiplied to 131 x 103 cells 3. Synthetic medium as in claim 1 or 2 in the culture medium with ferric citrate and to characterised in that it contains compounds of 82x103 cells in the cultivation medium with 70 biogenic trace elements, advantageou ' sly sele- ferric chloride. nium, zinc in a concentration of 0,002 to 2 mg/1.
Example 3 4. Synthetic medium as in one of claims 1 Cells of the hybridoma PLV-01 have been to 3 characterised in that it contains ascorbic inocculated in an amount of '10 X 103 cells to 75 acid in a concentration of 1 to 100 m911.
0,1 mi of basic components mentioned in 5. Synthetic medium as in one of claims 1 example 1. As supplement 5X 10-4 Mol/1 Of to 4 characterised in that it contains steroid potassium ferricyanide have been added into substances, advantageously hydrocortisone in the culture medium. After 3 days of cultivation a concentration of 0,0001 to 0,1 mg/i.
at the temperature of 37% and of 4,5% per 80 6. Synthetic medium as in one of claims 1 volume of carbon dioxide in a humidified at to 5 characterised in that it contains amines, mosphere at pH 7,4 of the medium the cells advantageously ethanolamine in a concentra have multiplied to 62 x 103. tion of 0. 1 to 15 mg/1.
7. Synthetic medium for hybridoma and
Claims (2)
- Example 4 85 myeloma cell cultivation as claimed in Claim 1Cells of the hybridoma PLV-01 have been substantially as described in any one of the inocculated in an amount of 10X 103 cells into examples disclosed herein.0,1 m] of basic components mentioned in Pub idhed 1988 at The Patent Office, State House, 66171 High Holborn, example 1. Iron sulphate in a concentration of London WC 1 R 4TP. Further copies may be obtained from 1 X 10-4 mol/1 has been added as supplement The Patent Office, Sales Branch, StMary Cray, Orpington, Kent BR5 3RD.Printed by Burgess & Son (Abingdon) Ltd. Con. 1187.into the culture medium. After 3 days of culti vation at a temperature of 37T and 4.5% per volume of carbon dioxide in a humidified at mosphere at pH 7,4 of the medium the cells have multiplied to 25 x 103.Example 5 Cells of the hybridoma PLV-01 have been inocculated in an amount of 10 X 103 into 0, 1 mi of protein-free culture medium of the com position as in example 1 placed in wells of a plastic cultivation microplate with 96 wells.For comparison cells of this hybridoma have been inocculated into a protein-free culture medium containing in addition to the basic medium as in example 1 solely ferric citrate (5 x 10-4 mol/l). After 3 days of cultivation at conditions as in example 1 the hybridoma cells have multiplied to 118 x 103 cells in the protein-free culture medium and to 103 x 103 cells in the protein-free culture medium where solely ferric citrate has been added.CLAIMS 1. Synthetic medium for hybridoma and myeloma cell cultivation comprising anorganic salts in a concentration of 5000 to 12000 mg/I, monosaccharides in a concentration of 300 to 5000 mg/1, amino acids in a concen tration of 200 to 5000 mg/1, vitamins in a concentration of 2 to 100 mg/1, substances buffering changes of pH in a concentration of to 20000 mg/1, possibly also sodium py ruvate, antibiotics, an indicator of pH changes and a supplement, characterised in that said supplement is formed by at least one water soluble iron compound in a concentration of 2 x 10-5 to 1 x 10-2 mol/1.
- 2. Synthetic medium as in claim 1, charac- terised in that the water soluble iron corn-
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS867158A CS262822B1 (en) | 1986-10-03 | 1986-10-03 | Synthetic medium for the cultivation of myelomic cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB8722473D0 GB8722473D0 (en) | 1987-10-28 |
| GB2196348A true GB2196348A (en) | 1988-04-27 |
| GB2196348B GB2196348B (en) | 1990-07-04 |
Family
ID=5420193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8722473A Expired - Lifetime GB2196348B (en) | 1986-10-03 | 1987-09-24 | Synthetic medium for hybridoma and myeloma cell cultivation. |
Country Status (4)
| Country | Link |
|---|---|
| CS (1) | CS262822B1 (en) |
| DE (1) | DE3733453A1 (en) |
| FR (1) | FR2604727B1 (en) |
| GB (1) | GB2196348B (en) |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990003430A1 (en) * | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| EP0432952A1 (en) * | 1989-12-07 | 1991-06-19 | Snow Brand Milk Products Co., Ltd. | Serum-free culture medium |
| EP0485689A1 (en) * | 1990-10-23 | 1992-05-20 | Rikagaku Kenkyusho | Cells growing in protein-free medium, and enhancing replication of exogenous genes |
| FR2671098A1 (en) * | 1990-12-28 | 1992-07-03 | Mogam Biotech Res Inst | HIGH DENSITY ENVIRONMENT FOR CULTURE OF ANIMAL CELLS. |
| WO1993000423A1 (en) * | 1991-06-21 | 1993-01-07 | Novo Nordisk A/S | Iron chelate culture medium additive |
| US5397706A (en) * | 1991-11-06 | 1995-03-14 | Correa; Paulo N. | Serum-free basal and culture medium for hematopoietic and leukemia cells |
| US5602183A (en) * | 1991-03-01 | 1997-02-11 | Warner-Lambert Company | Dermatological wound healing compositions and methods for preparing and using same |
| US5614561A (en) * | 1991-03-01 | 1997-03-25 | Warner-Lambert Company | Antihistamine-wound healing compositions and methods for preparing and using same |
| US5633285A (en) * | 1991-03-01 | 1997-05-27 | Warner-Lambert Company | Cytoprotective wound healing compositions and methods for preparing and using same |
| US5641814A (en) * | 1991-03-01 | 1997-06-24 | Warner-Lambert Company | Antikeratolytic-wound healing compositions and methods for preparing and using same |
| US5646190A (en) * | 1991-03-01 | 1997-07-08 | Warner-Lambert Company | Acne treating-wound healing compositions and methods for preparing and using same |
| US5648380A (en) * | 1991-03-01 | 1997-07-15 | Warner-Lambert Company | Anti-inflammatory wound healing compositions and methods for preparing and using same |
| US5652274A (en) * | 1991-03-01 | 1997-07-29 | Martin; Alain | Therapeutic-wound healing compositions and methods for preparing and using same |
| US5658957A (en) * | 1991-03-01 | 1997-08-19 | Warner Lambert Company | Immunostimulating wound healing compositions and method for preparing and using same |
| US5658956A (en) * | 1991-03-01 | 1997-08-19 | Warner-Lambert Company | Bioadhesive-wound healing compositions and methods for preparing and using same |
| US5663208A (en) * | 1991-03-01 | 1997-09-02 | Warner-Lambert Company | Antifungal wound healing compositions and methods for preparing and using same |
| US5674912A (en) * | 1991-03-01 | 1997-10-07 | Warner-Lambert Company | Sunscreen-wound healing compositions and methods for preparing and using same |
| US5692302A (en) * | 1991-03-01 | 1997-12-02 | Warner-Lambert Company | Razor cartridges comprising wound healing compositions and methods for preparing and using same |
| EP0763102A4 (en) * | 1994-04-21 | 1998-12-16 | Genzyme Corp | Serum-free medium supplement |
| US5856364A (en) * | 1991-03-01 | 1999-01-05 | Warner Lambert Company | Therapeutic antiviral-wound healing compositions and methods for preparing and using same |
| US5863938A (en) * | 1991-03-01 | 1999-01-26 | Warner Lambert Company | Antibacterial-wound healing compositions and methods for preparing and using same |
| US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| EP1360314A4 (en) * | 2001-02-15 | 2004-08-11 | Centocor Inc | Chemically defined medium for cultured mammalian cells |
| GB2404665A (en) * | 2003-08-08 | 2005-02-09 | Cambridge Antibody Tech | Culture medium for myeloma cells |
| WO2006108455A1 (en) * | 2004-11-02 | 2006-10-19 | Ares Trading S.A. | Serum-free cell culture medium for mammalian cells |
| USRE39792E1 (en) | 1990-10-17 | 2007-08-21 | Smithkline Beecham Corporation | Method for culturing Chinese hamster ovary cells |
| EA011749B1 (en) * | 2004-11-02 | 2009-06-30 | Арес Трейдинг С.А. | A process for the production of human growth hormone and use serum-free cell culture medium for mammalian cells expressing human growth hormone |
| US8273553B2 (en) | 2004-11-02 | 2012-09-25 | Ares Trading S.A. | Production of growth hormone in serum-free cell culture medium for mammalian cells |
| US9321996B2 (en) | 1996-08-30 | 2016-04-26 | Life Technologies Corporation | Serum-free mammalian cell culture medium, and uses thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3717029A1 (en) * | 1987-05-21 | 1988-12-15 | Behringwerke Ag | METHOD FOR PRODUCING ANIMAL SERUM WITH REDUCED PROTEASE AND INHIBITOR ACTIVITY, ANIMAL SERUM, AND USE OF THIS SERUM AS AN ADDITION TO CULTURAL MEDIA |
| DE10247873B4 (en) * | 2002-10-14 | 2005-11-17 | Tracto-Technik Gmbh | Device for cutting pipes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5863385A (en) * | 1981-10-02 | 1983-04-15 | ハナ・バイオロジツクス・インコ−ポレ−テツド | Culture medium for cell derived from immune system |
-
1986
- 1986-10-03 CS CS867158A patent/CS262822B1/en unknown
-
1987
- 1987-09-24 GB GB8722473A patent/GB2196348B/en not_active Expired - Lifetime
- 1987-10-02 DE DE19873733453 patent/DE3733453A1/en not_active Withdrawn
- 1987-10-02 FR FR878713651A patent/FR2604727B1/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| BIOTECHNOL LETT (1987)VOL 9(4)P259-64 * |
Cited By (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990003430A1 (en) * | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| EP0432952A1 (en) * | 1989-12-07 | 1991-06-19 | Snow Brand Milk Products Co., Ltd. | Serum-free culture medium |
| USRE41974E1 (en) | 1990-10-17 | 2010-11-30 | Glaxosmithkline Llc | Method for culturing Chinese hamster ovary cells |
| USRE39792E1 (en) | 1990-10-17 | 2007-08-21 | Smithkline Beecham Corporation | Method for culturing Chinese hamster ovary cells |
| EP0485689A1 (en) * | 1990-10-23 | 1992-05-20 | Rikagaku Kenkyusho | Cells growing in protein-free medium, and enhancing replication of exogenous genes |
| US5254462A (en) * | 1990-10-23 | 1993-10-19 | Rikagaku Kenkyusho | Animal cell line useful for expression of exogenous genes |
| FR2671098A1 (en) * | 1990-12-28 | 1992-07-03 | Mogam Biotech Res Inst | HIGH DENSITY ENVIRONMENT FOR CULTURE OF ANIMAL CELLS. |
| US5663208A (en) * | 1991-03-01 | 1997-09-02 | Warner-Lambert Company | Antifungal wound healing compositions and methods for preparing and using same |
| US5863938A (en) * | 1991-03-01 | 1999-01-26 | Warner Lambert Company | Antibacterial-wound healing compositions and methods for preparing and using same |
| US5641814A (en) * | 1991-03-01 | 1997-06-24 | Warner-Lambert Company | Antikeratolytic-wound healing compositions and methods for preparing and using same |
| US5646190A (en) * | 1991-03-01 | 1997-07-08 | Warner-Lambert Company | Acne treating-wound healing compositions and methods for preparing and using same |
| US5648380A (en) * | 1991-03-01 | 1997-07-15 | Warner-Lambert Company | Anti-inflammatory wound healing compositions and methods for preparing and using same |
| US5652274A (en) * | 1991-03-01 | 1997-07-29 | Martin; Alain | Therapeutic-wound healing compositions and methods for preparing and using same |
| US5658957A (en) * | 1991-03-01 | 1997-08-19 | Warner Lambert Company | Immunostimulating wound healing compositions and method for preparing and using same |
| US5658956A (en) * | 1991-03-01 | 1997-08-19 | Warner-Lambert Company | Bioadhesive-wound healing compositions and methods for preparing and using same |
| US5614561A (en) * | 1991-03-01 | 1997-03-25 | Warner-Lambert Company | Antihistamine-wound healing compositions and methods for preparing and using same |
| US5674912A (en) * | 1991-03-01 | 1997-10-07 | Warner-Lambert Company | Sunscreen-wound healing compositions and methods for preparing and using same |
| US5692302A (en) * | 1991-03-01 | 1997-12-02 | Warner-Lambert Company | Razor cartridges comprising wound healing compositions and methods for preparing and using same |
| US5602183A (en) * | 1991-03-01 | 1997-02-11 | Warner-Lambert Company | Dermatological wound healing compositions and methods for preparing and using same |
| US5856364A (en) * | 1991-03-01 | 1999-01-05 | Warner Lambert Company | Therapeutic antiviral-wound healing compositions and methods for preparing and using same |
| US5633285A (en) * | 1991-03-01 | 1997-05-27 | Warner-Lambert Company | Cytoprotective wound healing compositions and methods for preparing and using same |
| WO1993000423A1 (en) * | 1991-06-21 | 1993-01-07 | Novo Nordisk A/S | Iron chelate culture medium additive |
| US5397706A (en) * | 1991-11-06 | 1995-03-14 | Correa; Paulo N. | Serum-free basal and culture medium for hematopoietic and leukemia cells |
| EP0763102A4 (en) * | 1994-04-21 | 1998-12-16 | Genzyme Corp | Serum-free medium supplement |
| US9321996B2 (en) | 1996-08-30 | 2016-04-26 | Life Technologies Corporation | Serum-free mammalian cell culture medium, and uses thereof |
| EP1360314A4 (en) * | 2001-02-15 | 2004-08-11 | Centocor Inc | Chemically defined medium for cultured mammalian cells |
| GB2404665A (en) * | 2003-08-08 | 2005-02-09 | Cambridge Antibody Tech | Culture medium for myeloma cells |
| GB2404665B (en) * | 2003-08-08 | 2005-07-06 | Cambridge Antibody Tech | Cell culture |
| US8361797B2 (en) | 2003-08-08 | 2013-01-29 | Medimmune Limited | Myeloma cell culture in transferrin-free low iron medium |
| EA011749B1 (en) * | 2004-11-02 | 2009-06-30 | Арес Трейдинг С.А. | A process for the production of human growth hormone and use serum-free cell culture medium for mammalian cells expressing human growth hormone |
| JP4833991B2 (en) * | 2004-11-02 | 2011-12-07 | アレス トレーディング ソシエテ アノニム | Serum-free cell culture medium for mammalian cells |
| US8273553B2 (en) | 2004-11-02 | 2012-09-25 | Ares Trading S.A. | Production of growth hormone in serum-free cell culture medium for mammalian cells |
| US7709229B2 (en) | 2004-11-02 | 2010-05-04 | Ares Trading S.A. | Serum-free cell culture medium for mammalian cells |
| WO2006108455A1 (en) * | 2004-11-02 | 2006-10-19 | Ares Trading S.A. | Serum-free cell culture medium for mammalian cells |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2196348B (en) | 1990-07-04 |
| CS262822B1 (en) | 1989-04-14 |
| CS715886A1 (en) | 1988-08-16 |
| DE3733453A1 (en) | 1988-04-14 |
| GB8722473D0 (en) | 1987-10-28 |
| FR2604727A1 (en) | 1988-04-08 |
| FR2604727B1 (en) | 1990-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2196348A (en) | Synthetic medium for hybridoma and myeloma cell cultivation | |
| US4443546A (en) | Process and composition for propagating mammalian cells | |
| Goding | Antibody production by hybridomas | |
| Namba et al. | Immunocytology of Cultured IgM-Forming Cells of Mouse: I. Requirement of Phagocytic Cell Factor for the Growth of IgM-Forming Tumor Cells in Tissue Culture | |
| Ginsburg et al. | Specific anion binding to fructose diphosphate aldolase from rabbit muscle | |
| Miller et al. | Effects of dissolved oxygen concentration on hybridoma growth and metabolism in continuous culture | |
| JPS6229994A (en) | Production of l-ascorbic acid by bacteria | |
| Kovář et al. | Iron compounds at high concentrations enable hybridoma growth in a protein-free medium | |
| AU7126487A (en) | Production of proteins by cell culture | |
| US4404280A (en) | Process for preparing murine interleukin 2 in the presence of interleukin 1 from an interleukin 2 nonproducer malignant cell line and cell line therefor | |
| GB2134134A (en) | Novel cell lines for use in the preparation of hybridoma cells | |
| US4407945A (en) | Constitutive production of interleukin 2 by a T cell hybridoma | |
| JP6108170B2 (en) | Cell culture media | |
| Choppin et al. | Characterization of erythropoietin produced by IW32 murine erythroleukemia cells | |
| Roon et al. | [37a] ATP: Urea amidolyase (ADP)(Candida utilis) | |
| Brandwein et al. | Production and characterization of monoclonal antibodies to soluble rat lung guanylate cyclase. | |
| Hokama et al. | Cross‐reactivity of ciguatoxin, okadaic acid, and polyethers with monoclonal antibodies | |
| US2893988A (en) | Therapeutically valuable substances pertaining to the group of vitamins b12 | |
| RU2018532C1 (en) | Nutrient medium for cultivation person/human hybridon (its variants) | |
| US5409827A (en) | Blended bovine sera cellular growth media and their methods of production and use | |
| Peterson et al. | Amino acid incorporation in developing Fucus embryos | |
| US4968618A (en) | Composition and method for promoting growth of granulocytes | |
| Okabe et al. | Long-term cultivation of a human colony-stimulating factor-producing cell line in a protein-free chemically defined medium | |
| CN113005082B (en) | T cell serum-free culture medium and application thereof | |
| Rajeswaran et al. | Structure of DL-selenomethionine, C5H11NO2Se |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19920924 |